BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24900060)

  • 1. Dual-time-point FDG PET/CT: Is It Useful for Lymph Node Staging in Patients with Non-Small-Cell Lung Cancer?
    Kim DW; Kim WH; Kim CG
    Nucl Med Mol Imaging; 2012 Sep; 46(3):196-200. PubMed ID: 24900060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship Between Dual-Time Point FDG PET and Immunohistochemical Parameters in Preoperative Colorectal Cancer: Preliminary Study.
    Lee JH; Lee WA; Park SG; Park DK; Namgung H
    Nucl Med Mol Imaging; 2012 Mar; 46(1):48-56. PubMed ID: 24900032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour.
    Nishiyama Y; Yamamoto Y; Monden T; Sasakawa Y; Tsutsui K; Wakabayashi H; Ohkawa M
    Nucl Med Commun; 2005 Oct; 26(10):895-901. PubMed ID: 16160649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary clinical assessment of dynamic
    Shinya T; Otomi Y; Kubo M; Kinoshita M; Takechi K; Uyama N; Yamanaka M; Terazawa K; Toba H; Bando Y; Otsuka H; Harada M
    Ann Nucl Med; 2019 Jun; 33(6):414-423. PubMed ID: 30911883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients.
    Vansteenkiste JF; Stroobants SG; De Leyn PR; Dupont PJ; Bogaert J; Maes A; Deneffe GJ; Nackaerts KL; Verschakelen JA; Lerut TE; Mortelmans LA; Demedts MG
    J Clin Oncol; 1998 Jun; 16(6):2142-9. PubMed ID: 9626214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual time point imaging for F18-FDG-PET/CT does not improve the accuracy of nodal staging in non-small cell lung cancer patients.
    Rogasch JM; Steffen IG; Riedel S; Apostolova I; Wertzel H; Achenbach HJ; Steinkrüger FL; Kalinski T; Schultz M; Schreiber J; Amthauer H; Furth C
    Eur Radiol; 2016 Aug; 26(8):2808-18. PubMed ID: 26560731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.
    Shimizu K; Okita R; Saisho S; Yukawa T; Maeda A; Nojima Y; Nakata M
    Ann Nucl Med; 2015 Dec; 29(10):854-60. PubMed ID: 26254228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-time-point FDG PET for the evaluation of locoregional lymph nodes in thoracic esophageal squamous cell cancer.
    Hu Q; Wang W; Zhong X; Yuan S; Fu Z; Guo H; Yu J
    Eur J Radiol; 2009 May; 70(2):320-4. PubMed ID: 18602239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: is dual time point imaging worth the effort?
    Yen RF; Chen KC; Lee JM; Chang YC; Wang J; Cheng MF; Wu YW; Lee YC
    Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1305-15. PubMed ID: 18283453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Significance of dual-time-point 18F-FDG PET imaging in evaluation of hilar and mediastinal lymph node metastasis in non-small-cell lung cancer].
    Hu M; Yu JM; Liu NB; Liu LP; Guo HB; Yang GR; Zhang PL; Xu XQ
    Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):306-9. PubMed ID: 18788639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ratio of Mediastinal Lymph Node SUV to Primary Tumor SUV in
    Cho J; Choe JG; Pahk K; Choi S; Kwon HR; Eo JS; Seo HJ; Kim C; Kim S
    Nucl Med Mol Imaging; 2017 Jun; 51(2):140-146. PubMed ID: 28559938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual-time point
    Park S; Paeng JC; Kang CH; Cheon GJ; Kang KW; Chung JK; Lee DS
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1317-1328. PubMed ID: 29502309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic ability of
    Lee JW; Kim EY; Kim DJ; Lee JH; Kang WJ; Lee JD; Yun M
    Eur Radiol; 2016 Dec; 26(12):4515-4523. PubMed ID: 26943133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy and predictive features of FDG-PET/CT and CT for diagnosis of lymph node metastasis of T1 non-small-cell lung cancer manifesting as a subsolid nodule.
    Lee SM; Park CM; Paeng JC; Im HJ; Goo JM; Lee HJ; Kang CH; Kim YW; Kim JI
    Eur Radiol; 2012 Jul; 22(7):1556-63. PubMed ID: 22358427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-time-point FDG-PET for evaluation of lymph node metastasis in patients with non-small-cell lung cancer.
    Nishiyama Y; Yamamoto Y; Kimura N; Ishikawa S; Sasakawa Y; Ohkawa M
    Ann Nucl Med; 2008 May; 22(4):245-50. PubMed ID: 18535874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual time point FDG PET for evaluation of malignant pleural mesothelioma.
    Yamamoto Y; Kameyama R; Togami T; Kimura N; Ishikawa S; Yamamoto Y; Nishiyama Y
    Nucl Med Commun; 2009 Jan; 30(1):25-9. PubMed ID: 19306511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. F-18-FDG-avid lymph node metastasis along preferential lymphatic drainage pathways from the tumor-bearing lung lobe on F-18-FDG PET/CT in patients with non-small-cell lung cancer.
    Shigemoto Y; Suga K; Matsunaga N
    Ann Nucl Med; 2016 May; 30(4):287-97. PubMed ID: 27007128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ratio of Lymph Node to Primary Tumor SUV on PET/CT Accurately Predicts Nodal Malignancy in Non-Small-Cell Lung Cancer.
    Mattes MD; Moshchinsky AB; Ahsanuddin S; Rizk NP; Foster A; Wu AJ; Ashamalla H; Weber WA; Rimner A
    Clin Lung Cancer; 2015 Nov; 16(6):e253-8. PubMed ID: 26163919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-time-point F-18 FDG PET/CT for evaluation of intrathoracic lymph nodes in patients with non-small cell lung cancer.
    Shinya T; Rai K; Okumura Y; Fujiwara K; Matsuo K; Yonei T; Sato T; Watanabe K; Kawai H; Sato S; Kanazawa S
    Clin Nucl Med; 2009 Apr; 34(4):216-21. PubMed ID: 19300050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-phase 18F-FDG PET/CT imaging in the characterization of pancreatic lesions: does it offer prognostic information?
    Santhosh S; Mittal BR; Bhasin D; Rana SS; Bhattacharya A; Srinivasan R; Nada R; Gupta R
    Nucl Med Commun; 2014 Oct; 35(10):1018-25. PubMed ID: 25023999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.